Zobrazeno 1 - 10
of 35
pro vyhledávání: '"H. Jafferbhoy"'
Autor:
Cher Shiong Chuah, Ian D. Arnott, Nikolas Plevris, Gareth R. Jones, Wai Liam Lam, Rebecca Hall, Amy Tyler, S Siakavellas, Jayne Saunders, Philip Jenkinson, Claire Kane, Jennifer Veryan, Andrew Robertson, Graham Naismith, Gillian H Bain, Iona Campbell, L Potts, Christopher Kelly, Daniel R. Gaya, Craig Mowat, H. Jafferbhoy, James Fulforth, John Paul Seenan, Diarmid Ian Sutherland, Charlie W. Lees, David Watts, Jonathan Macdonald
Publikováno v:
Journal of Gastroenterology and Hepatology. 36:2067-2075
BACKGROUND AND AIM Ustekinumab is a monoclonal antibody that targets interleukin-12/23. In Scotland, it was approved for the treatment of moderate to severe Crohn's disease in 2017. The objective of this study was to establish the real-world effectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7eef0e05b51c3388fd468aec01e6e0d
https://doi.org/10.1111/jgh.15390
https://doi.org/10.1111/jgh.15390
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol 2010, Iss default, Pp 87-96 (2010)
H Jafferbhoy, W Gashau, JF DillonGut Group, Biomedical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, UKAbstract: Chronic hepatitis C1 is a common cause of liver disease worldwide. It is a slow and progressiv
Externí odkaz:
https://doaj.org/article/9d71267d0edd456a8c2f53efb7986189
Publikováno v:
British Journal of Surgery. 108
Aims Despite the widespread use of endoscopy, upper gastrointestinal (UGI) cancers still present at an advanced stage. As survival is closely linked to stage and time of diagnosis, failure to detect subtle precancerous changes at endoscopy may compou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6016a21c4c4a83c567fdaf32caba1526
https://doi.org/10.1093/bjs/znab361.116
https://doi.org/10.1093/bjs/znab361.116
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Gillian H Bain, Ian D. Arnott, Philip Jenkinson, David Watts, Wai Lam, Craig Mowat, Nikolas Plevris, Jennifer Veryan, Daniel R. Gaya, H. Jafferbhoy, Cher Chuah, Diarmid Ian Sutherland, Iona Campbell, Charlie W. Lees, John-Paul Sennan, Andrew Robertson, Jennifer Saunders, Christopher Kelly, Gareth R. Jones, James Fulforth, Jonathan Macdonald, Rebecca Hall, Graham Naismith, Claire Kane
Publikováno v:
Posters.
Introduction Ustekinumab (UST) is an anti-IL12/23 biologic licensed for the treatment of moderate to severe Crohn’s disease (CD). The aims of this study were to establish the long-term real-world effectiveness and safety of UST for the treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1665ef855d5d1680e0595bee50873f66
https://doi.org/10.1136/gutjnl-2020-bsgcampus.210
https://doi.org/10.1136/gutjnl-2020-bsgcampus.210
Autor:
Cher Shiong Chuah, Gareth-Rhys Jones, Jennifer Veryan, Shahida Din, Nikolas Plevris, Mathew Lyons, P. Shasi, Angus Watson, John Todd, E. Saffouri, A Sengupta, Paul Brennan, Graham Naismith, M Groome, L Potts, Antonia M. D. Churchhouse, R. M. Allen, Philip Jenkinson, E. Donoghue, Craig Mowat, Daniel R. Gaya, W. L. Lam, S. Chaudhary, H. Jafferbhoy, Morag Jane MacMaster, David Watts, John Paul Seenan, I. D. R. Arnott, Diarmid Ian Sutherland, Charlie W. Lees, Jonathan Macdonald
Publikováno v:
Journal of Crohn'scolitis. 13(9)
Background & Aims Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn’s disease and ulcerative colitis. The aims of this study were to establish the real-world effectiveness and safety of v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f53251f3e36ffbf10facb503cb35c0b0
https://pubmed.ncbi.nlm.nih.gov/30768123
https://pubmed.ncbi.nlm.nih.gov/30768123
Autor:
Daniel R. Gaya, P Shasi, D Watts, Charlie W. Lees, P Baker, H Jafferbhoy, C Mowat, Emma Donoghue, John Paul Seenan, Andrea K Watson, Graham Naismith, E Saffouri, Morag MacMaster, John Todd, Nikolas Plevris, Max Groome, Phil Jenkinson, L Potts, Cher Chuah, Alan G. Shand, Colin L. Noble, Antonia M. D. Churchhouse, Jonathan Macdonald, Eleanor F Watson, J Veryan, A Sengupta, Paul Brennan, Shahida Din, R Allen, I. D. R. Arnott, G R Jones
Publikováno v:
IBD.
Introduction The GEMINI trials and an increasing body of real-world data have demonstrated the effectiveness and safety of vedolizumab (VDZ) in IBD. However, there is limited available data about its effect on hospitalisations and steroid use. Our ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a262bbd8a13cb16d3bbd55614f40c405
https://doi.org/10.1136/gutjnl-2018-bsgabstracts.177
https://doi.org/10.1136/gutjnl-2018-bsgabstracts.177
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Epidemiology and Infection. 140:1048-1053
SUMMARYIn Scotland, an estimated 1% of the population is infected with hepatitis C virus (HCV). There is ethnic diversity in Scotland, with a large Pakistani sub-population. Our aim was to investigate the prevalence of HCV in an immigrant Pakistani p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a539d4dc9ee294dba007762445e65940
https://doi.org/10.1017/s095026881100152x
https://doi.org/10.1017/s095026881100152x